GlassScriptPhysician profile
Shardea Turney
NPI 1841882479
$9,898.98
in general payments reported to CMS, 2019-2025
16 companies · $522 in 2025
The $522 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $141 · 2022: $3,623 · 2023: $4,679 · 2024: $935 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,154 · Travel and Lodging: $2,927 · Education: $54.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,154.18 |
| Travel and Lodging | $2,926.73 |
| Education | $54.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,753.15 | 2022-2025 | Synchromedii, Intellis Adaptivestim, Inceptiv |
| Boston Scientific Corporation | $2,441.67 | 2022-2025 | Intracept, General - Pain Management, Wavewriter Alpha Prime 16 |
| Relievant Medsystems, INC. | $1,296.66 | 2023 | Intracept |
| Nalu Medical, INC. | $830.02 | 2022-2024 | Nalu Neurostimulation System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $608.96 | 2022-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $338.44 | 2023-2025 | Belbuca, Xtampza |
| Nevro Corp. | $141.40 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $101.73 | 2024-2025 | |
| Abbvie INC. | $82.66 | 2024-2025 | |
| Si-Bone, INC. | $76.37 | 2024-2025 | |
| Spr Therapeutics, INC | $66.52 | 2022-2025 | Sprint Pns System |
| Ani Pharmaceuticals, INC. | $52.08 | 2025 | Purified Cortrophin Gel |
| Saluda Medical Americas, INC. | $35.53 | 2024 | Evoke |
| Spinal Simplicity, LLC | $30.26 | 2024 | Ha Minuteman G3-R |
| Averitas Pharma INC. | $29.53 | 2023 | Qutenza |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valinor Pharma, LLC | $14.00 | 2025 | Movantik |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shardea Turney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.